Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk
- PMID: 20026811
- PMCID: PMC2815723
- DOI: 10.1093/jnci/djp467
Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk
Abstract
Background: Consumption of Chinese herbs that contain aristolochic acid (eg, Mu Tong) has been associated with an increased risk of urinary tract cancer.
Methods: We conducted a population-based case-control study in Taiwan to examine the association between prescribed Chinese herbal products that contain aristolochic acid and urinary tract cancer. All patients newly diagnosed with urinary tract cancer (case subjects) from January 1, 2001, to December 31, 2002, and a random sample of the entire insured population from January 1, 1997, to December 31, 2002 (control subjects), were selected from the National Health Insurance reimbursement database. Subjects who were ever prescribed more than 500 pills of nonsteroidal anti-inflammatory drugs and/or acetaminophen were excluded, leaving 4594 case patients and 174,701 control subjects in the final analysis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multivariable logistic regression models for the association between prescribed Chinese herbs containing aristolochic acid and the occurrence of urinary tract cancer. Models were adjusted for age, sex, residence in a township where black foot disease was endemic (an indicator of chronic arsenic exposure from drinking water [a risk factor for urinary tract cancer]), and history of chronic urinary tract infection. Statistical tests were two-sided.
Results: Having been prescribed more than 60 g of Mu Tong and an estimated consumption of more than 150 mg of aristolochic acid were independently associated with an increased risk for urinary tract cancer in multivariable analyses (Mu Tong: at 61-100 g, OR = 1.6, 95% CI = 1.3 to 2.1, and at >200 g, OR = 2.1, 95% CI = 1.3 to 3.4; aristolochic acid: at 151-250 mg, OR = 1.4, 95% CI = 1.1 to 1.8, and at >500 mg, OR = 2.0, 95% CI = 1.4 to 2.9). A statistically significant linear dose-response relationship was observed between the prescribed dose of Mu Tong or the estimated cumulative dose of aristolochic acid and the risk of urinary tract cancer (P < .001 for both).
Conclusions: Consumption of aristolochic acid-containing Chinese herbal products is associated with an increased risk of cancer of the urinary tract in a dose-dependent manner that is independent of arsenic exposure.
Comment in
-
Re: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.J Natl Cancer Inst. 2010 Jul 7;102(13):988; author reply 988-90. doi: 10.1093/jnci/djq180. Epub 2010 May 17. J Natl Cancer Inst. 2010. PMID: 20479292 No abstract available.
Similar articles
-
Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid.PLoS One. 2014 Aug 29;9(8):e105218. doi: 10.1371/journal.pone.0105218. eCollection 2014. PLoS One. 2014. PMID: 25170766 Free PMC article.
-
Re: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.J Natl Cancer Inst. 2010 Jul 7;102(13):988; author reply 988-90. doi: 10.1093/jnci/djq180. Epub 2010 May 17. J Natl Cancer Inst. 2010. PMID: 20479292 No abstract available.
-
Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study.Am J Kidney Dis. 2010 Mar;55(3):507-18. doi: 10.1053/j.ajkd.2009.10.055. Epub 2010 Feb 8. Am J Kidney Dis. 2010. PMID: 20116155
-
Risk assessment of upper tract urothelial carcinoma related to aristolochic acid.Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):812-20. doi: 10.1158/1055-9965.EPI-12-1386. Epub 2013 Mar 5. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23462915 Free PMC article. Review.
-
Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.Environ Mol Mutagen. 2013 Jan;54(1):1-7. doi: 10.1002/em.21756. Epub 2012 Dec 13. Environ Mol Mutagen. 2013. PMID: 23238808 Review.
Cited by
-
Diagnosing upper tract urothelial carcinoma: A review of the role of diagnostic ureteroscopy and novel developments over last two decades.Asian J Urol. 2024 Apr;11(2):242-252. doi: 10.1016/j.ajur.2022.08.003. Epub 2022 Sep 23. Asian J Urol. 2024. PMID: 38680592 Free PMC article. Review.
-
Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation.J Clin Med. 2024 Mar 24;13(7):1872. doi: 10.3390/jcm13071872. J Clin Med. 2024. PMID: 38610636 Free PMC article.
-
Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.Nat Commun. 2023 Jul 17;14(1):4274. doi: 10.1038/s41467-023-39981-6. Nat Commun. 2023. PMID: 37460463 Free PMC article.
-
Trends and sex-specific incidence of upper urinary tract cancer in Taiwan: A birth cohort study.Cancer Med. 2023 Jul;12(14):15350-15357. doi: 10.1002/cam4.6084. Epub 2023 Jul 1. Cancer Med. 2023. PMID: 37392179 Free PMC article.
-
Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study.J Cancer Res Clin Oncol. 2023 Sep;149(11):8201-8211. doi: 10.1007/s00432-023-04771-6. Epub 2023 Apr 15. J Cancer Res Clin Oncol. 2023. PMID: 37061628
References
-
- Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387–391. - PubMed
-
- Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs [letter] Lancet. 1994;343(8890):174. - PubMed
-
- Cosyns JP. Aristolochic acid and ‘‘Chinese herbs nephropathy’’: a review of the evidence to date. Drug Saf. 2003;26(1):33–48. - PubMed
-
- Nortier JL, Martinez M-CM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med. 2000;342(23):1686–1692. - PubMed
-
- Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis. 1999;33(6):1011–1017. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials